Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Respiratory vaccines R&D by Year
Respiratory vaccines R&D (FY2022–FY2024 sub-disaggregation) ($M) ($M)
Moderna Respiratory vaccines R&D: $837M in FY2024, down 46.1% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2024
837
Period ended Dec 31, 2024
Change on a year earlier
-46.1%
1,554 in FY2023
History
3 years
Since FY2022
Sources
1
FY2024 10-K
Where the FY2024 figure comes from
“Respiratory vaccines | $ | 837 | $ | 1,554 | $ | 1,363”
Source: FY2024 10-K ↗
Reported in FY2024 Form 10-K Item 7 (MD&A).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Respiratory vaccines R&D (FY2022–FY2024 sub-disaggregation) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 837 | -46.1% | FY2024 10-K ↗ |
| FY2023 | Dec 31, 2023 | 1,554 | +14.0% | FY2024 10-K ↗ |
| FY2022 | Dec 31, 2022 | 1,363 | – | FY2024 10-K ↗ |
Cite this data
StockData. (2026). Moderna Respiratory vaccines R&D ($M), annual FY2022–FY2024 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rd-respiratory-vaccines-leg
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.